Immunological Targeting of CD-133 in Recurrent Glioblastoma: A Multi-center Phase I Translational and Clinical Study of an Autologous CD-133 DC Vaccine

Trial Profile

Immunological Targeting of CD-133 in Recurrent Glioblastoma: A Multi-center Phase I Translational and Clinical Study of an Autologous CD-133 DC Vaccine

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 06 Jun 2017

At a glance

  • Drugs ICT 121 (Primary)
  • Indications Glioblastoma
  • Focus Adverse reactions
  • Sponsors ImmunoCellular Therapeutics
  • Most Recent Events

    • 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 05 Jun 2017 Results (n=20) from this trial published in an ImmunoCellular Therapeutics Media Release.
    • 09 Mar 2017 According to an ImmunoCellular Therapeutics media release, an abstract to ASCO has been submitted, with the goal of presenting preliminary results from this trial at the annual conference in June 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top